



06.05.2026		
11:00 - 12:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 1	Munich Hall
11:00 - 12:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 2	Hamburg Hall
11:00 - 12:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 3	Frankfurt Hall
12:45 - 13:30	Type: Opening and award lecture Title: Welcome to the ESMO Breast Cancer 2026 and award lecture 2026 Chair(s): Nicholas Turner, United Kingdom; Sara Tolaney, United States of America; Masakazu Toi, Japan	Berlin Hall

12:45 - 13:00 **Opening session**
Nicholas Turner¹, Sara Tolaney², Masakazu Toi³, ¹The Royal Marsden Hospital - Chelsea, London, United Kingdom, ²Dana Farber Cancer Institute, Boston, United States of America, ³Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan

13:00 - 13:05 **Introduction to the ESMO Breast Cancer 2026 award lecture**

13:05 - 13:30 **ESMO Breast Cancer 2026 award lecture - to be announced**

13:30 - 15:00	Type: Special Symposium Title: Immunotherapy in early stage breast cancer Chair(s): Giampaolo Bianchini, Italy; Shigehira Saji, Japan	Berlin Hall
----------------------	---	--------------------

13:30 - 13:35 **Introduction and scientific background**

13:35 - 13:50 **Leveraging breast cancer biological heterogeneity to tailor immunotherapy**

Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands

13:50 - 14:05 **Early TNBC and immunotherapy: Insights gained from clinical trials and remaining questions**

Giampaolo Bianchini, IRCCS Ospedale San Raffaele, Milan, Italy

14:05 - 14:20 **Pushing the boundaries: Immunotherapy for ER and HER2-positive early breast cancer**

Rebecca Dent, NCCS - National Cancer Centre Singapore, Singapore, Singapore

14:20 - 14:35 **Immunotherapy after neoadjuvant treatment in TNBC: Evidence, uncertainties, and future direction**

Shigehira Saji, Fukushima Medical University, Fukushima, Japan

14:35 - 15:00 **Q&A/Conclusions and clinical perspectives**



13:30 - 15:00	<p>Type: Educational session Title: New technologies for treatment decisions Chair(s): Christine Desmedt, Belgium; Carsten Denkert, Germany</p>	Munich Hall
13:30 - 13:50	<p>Novel proteomic technologies <u>Bernhard Kuster</u>, Technical University Munich, Freising, Germany</p>	
13:50 - 14:10	<p>CtDNA technologies <u>David Cescon</u>, Princess Margaret Cancer Centre, Toronto, Canada</p>	
14:10 - 14:30	<p>Tumor avatars to model patient responses <u>Daniela Thommen</u>, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands</p>	
14:30 - 14:50	<p>Dissecting the tumor microenvironment with spatial omics <u>Diether Lambrechts</u>, VIB-KULeuven Center for Cancer Biology (CCB), Leuven, Belgium</p>	
14:50 - 15:00	<p>Q&A and discussion</p>	
15:10 - 15:40	<p>Type: Keynote lecture Title: Keynote lecture - Lobular breast cancer: Special treatment considerations</p>	Berlin Hall
15:10 - 15:15	<p>Introduction by the Chair</p>	
15:15 - 15:40	<p>Lobular breast cancer: Special treatment considerations <u>Rinath Jeselsohn</u>, Dana Farber Cancer Institute - Longwood Center, Boston, United States of America</p>	
16:00 - 17:30	<p>Type: Proffered Paper session Title: Proffered Paper session 1</p>	Berlin Hall
16:00 - 17:30	<p>Type: Educational session Title: Lifestyle modifications and breast cancer Chair(s): Neil Iyengar, United States of America; Ines Vaz-Luis, France</p>	Munich Hall
16:00 - 16:20	<p>Lifestyle and breast cancer: What the evidence tells us (focus on evidence from population data and also some mechanistic data) <u>Neil Iyengar</u>, Winship Cancer Institute of Emory University, Atlanta, United States of America</p>	
16:20 - 16:40	<p>From clinic to life: Integrating lifestyle interventions in oncology care (focus on data from randomized controlled trials) <u>Anne May</u>, UMC - University Medical Center Utrecht, Utrecht, Netherlands</p>	
16:40 - 17:00	<p>Scaling lifestyle interventions: Digital tools and equity in access <u>Maria Alice Franco</u>, Institut Gustave Roussy, Villejuif, France</p>	



17:00 - 17:20 **Patient perspectives: Challenges and motivators**
Darryl Edwards, Primal Play, London, United Kingdom

17:20 - 17:30 **Q&A and discussion**

17:45 - 18:45	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 4	Munich Hall
17:45 - 18:45	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 5	Hamburg Hall
17:45 - 18:45	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 6	Frankfurt Hall



07.05.2026		
08:30 - 10:00	Type: Mini Oral session Title: Mini Oral session 1	Berlin Hall
08:30 - 10:00	Type: Educational session Title: Management of metastatic and early HER2+: Integrating new treatment strategies Chair(s): Javier Cortés, Spain; Cristina Saura Manich, Spain	Munich Hall
08:30 - 08:50	From clinical criteria to actionable biomarkers: Guiding neoadjuvant and adjuvant strategies in early breast cancer through precision medicine <u>Nadia Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, Germany	
08:50 - 09:10	From "one-size-fits-all" to tailored therapy: Moving beyond the CLEOPATRA regimen in first-line treatment of metastatic breast cancer <u>Sara Tolaney</u> , Dana Farber Cancer Institute, Boston, United States of America	
09:10 - 09:30	Making sense of sequencing: Personalizing metastatic breast cancer therapy based on approved treatments and patients' prior therapeutic history <u>Cristina Saura Manich</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
09:30 - 09:50	What's next for HER2-positive breast cancer? Promising new therapies reshaping the future treatment landscape <u>Javier Cortés</u> , IBCC - International Breast Cancer Center, Barcelona, Spain	
09:50 - 10:00	Q&A and discussion	
10:30 - 12:00	Type: Special Symposium Title: Treatment on the horizon: Next generation precision therapy for HR+ breast cancer Chair(s): Mafalda Oliveira, Spain; Seock-Ah Im, Republic of Korea	Berlin Hall
10:30 - 10:35	Introduction and scientific background	
10:35 - 10:50	New frontiers in CDK inhibition: Translating mechanisms into outcomes <u>Mafalda Oliveira</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
10:50 - 11:05	Rewiring transcription: From histone acetylation to KAT6A inhibition in breast cancer therapy <u>Geoff Lindeman</u> , WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, Australia	
11:05 - 11:20	Targeting the drivers: Mutation-specific inhibitors for PIK3CA, AKT1, and TP53 in breast cancer <u>Seock-Ah Im</u> , SNUH - Seoul National University Hospital, Seoul, Republic of Korea	



11:20 - 11:35 **Markers of treatment response and resistance: What we know and what we don't know**
Christine Desmedt, KU Leuven, Leuven, Belgium

11:35 - 12:00 **Q&A/Conclusions and clinical perspectives**

10:30 - 12:00 **Type: Educational session** **Munich Hall**
Title: Genetic testing and care for patients with breast cancer risk
Chair(s): Judy Garber, United States of America; Rita Schmutzler, Germany

10:30 - 10:45 **Comprehensive risk assessment for breast cancer**
Judy Garber, Dana Farber Cancer Institute, Boston, United States of America

10:45 - 11:00 **Clinical utility of breast cancer germline multipanel testing**
Nicholas Turner, The Royal Marsden Hospital - Chelsea, London, United Kingdom

11:00 - 11:15 **Risk reducing surgery and survival in BRCA mutation carriers**
Matteo Lambertini, Università degli Studi di Genova, Genoa, Italy

11:15 - 11:30 **Targeted therapy for BRCA mutation carriers**
Judith Balmaña, Vall d'Hebron University Hospital, Barcelona, Spain

11:30 - 11:45 **Risk-adjusted breast cancer surveillance**
Suzette Delaloge, Institut Gustave Roussy, Villejuif, France

11:45 - 12:00 **Q&A and discussion**

12:00 - 12:45 **Type: Poster Display session** **Exhibition area**
Title: Poster Display session

12:45 - 13:45 **Type: Industry Satellite Symposium** **Munich Hall**
Title: Industry Satellite Symposium - Slot 7

12:45 - 13:45 **Type: Industry Satellite Symposium** **Hamburg Hall**
Title: Industry Satellite Symposium - Slot 8

12:45 - 13:45 **Type: Industry Satellite Symposium** **Frankfurt Hall**
Title: Industry Satellite Symposium - Slot 9

13:15 - 14:00 **Type: Young Oncologists session** **Discussion hub**
Title: YO mentorship session 1

14:00 - 15:30 **Type: Proffered Paper session** **Berlin Hall**
Title: Proffered Paper session 2

14:00 - 15:30 **Type: Educational session** **Munich Hall**
Title: Special situations in breast cancer: Male breast cancer, brain metastases and BC during pregnancy



- 14:00 - 14:20 **Male breast cancer: Biology and management**
Sharon Giordano, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- 14:20 - 14:40 **Brain metastases: Management and new perspectives**
Rupert Bartsch, Medizinische Universitaet Wien, Vienna, Austria
- 14:40 - 15:00 **Breast cancer and pregnancy: Biology and treatment**
Fedro Peccatori, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy
- 15:00 - 15:20 **Navigating over- and undertreatment in frail patients**
Etienne Brain, Hopital René Huguenin - Institut Curie, Saint-Cloud, France
- 15:20 - 15:30 **Q&A and discussion**

16:00 - 17:30	Type: Educational session Title: Adjuvant therapy for ER positive breast cancer Chair(s): Stephen Johnston, United Kingdom; Sibylle Loibl, Germany	Berlin Hall
----------------------	--	--------------------

16:00 - 16:20 **Molecular heterogeneity of ER+ early stage BC**
Carsten Denkert, Philipps University Marburg, Marburg, Germany

16:20 - 16:40 **Oral SERDs for early breast cancer (eBC): How will they be used?**
François Clément Bidard, Institut Curie, Paris, France

16:40 - 17:00 **Adjuvant CDK 4/6 inhibitors: Could they replace chemotherapy for intermediate risk ER+ eBC?**
Stephen Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, United Kingdom

17:00 - 17:20 **The role of ctDNA monitoring in ER+ eBC: Could it change practice?**
Heather Parsons, Fred Hutchinson Cancer Research Center, Seattle, United States of America

17:20 - 17:30 **Q&A and discussion**

16:00 - 17:30	Type: Young Oncologists session Title: YO clinical cases	Hamburg Hall
17:40 - 18:25	Type: Young Oncologists session Title: YOC Vesalius talk	Discussion hub
17:45 - 18:45	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 10	Munich Hall



17:45 - 18:45	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 11	Hamburg Hall
17:45 - 18:45	Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 12	Frankfurt Hall



08.05.2026		
08:30 - 10:00	Type: Mini Oral session Title: Mini Oral session 2	Berlin Hall
08:30 - 10:00	Type: Special Symposium Title: New antibodies: ADCs, bispecifics Chair(s): Giuseppe Curigliano, Italy; Barbara Pistilli, France	Munich Hall
08:30 - 08:35	Introduction and scientific background	
08:35 - 08:50	Unlocking the potential of ADCs to improve outcomes in metastatic cancers <u>Barbara Pistilli</u> , Institut Gustave Roussy, Villejuif, France	
08:50 - 09:05	Moving ADCs to earlier lines and to the curative setting. <u>Giuseppe Curigliano</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy	
09:05 - 09:20	Bispecific innerbodies for breast cancer <u>Erika Hamilton</u> , Sarah Cannon Research Institute - Cancer Centre, Nashville, United States of America	
09:20 - 09:35	Opportunities and challenges of radioligand therapy in breast cancer <u>Sibylle Loibl</u> , GBG - German Breast Group Forschungs GmbH, Neu-Isenburg, Germany	
09:35 - 10:00	Q&A/Conclusions and clinical perspectives	
10:30 - 12:00	Type: Educational session Title: Treatment sequencing in metastatic ER+ breast cancer Chair(s): Komal Jhaveri, United States of America; Yeon Hee Park, Republic of Korea	Berlin Hall
10:30 - 10:50	New targets and improving performance of CDK4/6 inhibitors for ER-positive mBC <u>Komal Jhaveri</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, United States of America	
10:50 - 11:10	Upgrading endocrine backbone <u>Wolfgang Janni</u> , Ulm Medical University, Ulm, Germany	
11:10 - 11:30	Revolutionizing monitoring platform for molecular evolution <u>Nicholas Turner</u> , The Royal Marsden Hospital - Chelsea, London, United Kingdom	
11:30 - 11:50	Novel agents to target the PI3K pathway <u>Yeon Hee Park</u> , Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea	
11:50 - 12:00	Q&A and discussion	



10:30 - 12:00	<p>Type: Breast Cancer in Young Women (BCY) session Title: Breast Cancer in Young Women (BCY) session - Management of HR+ breast cancer in young women</p> <p>Chair(s): Shani Paluch-Shimon, Israel; Matteo Lambertini, Italy</p>	Munich Hall
10:30 - 10:50	<p>Biological considerations & therapeutic implications of genomic testing</p> <p><u>Nadia Harbeck</u>, Ludwig Maximilians University - Grosshadern, Munich, Germany</p>	
10:50 - 11:10	<p>The challenges of optimizing endocrine therapy</p> <p><u>Ann H. Partridge</u>, Dana Farber Cancer Institute, Boston, United States of America</p>	
11:10 - 11:30	<p>Survivorship care to promote adherence</p> <p><u>Shani Paluch-Shimon</u>, Hadassah University Hospital - Ein Kerem, Jerusalem, Israel</p>	
11:30 - 11:50	<p>Onco-fertility counselling 2026: New considerations</p> <p><u>Fedro Peccatori</u>, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy</p>	
11:50 - 12:00	<p>Q&A and discussion</p>	
12:15 - 13:15	<p>Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 13</p>	Munich Hall
12:15 - 13:15	<p>Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 14</p>	Hamburg Hall
12:15 - 13:15	<p>Type: Industry Satellite Symposium Title: Industry Satellite Symposium - Slot 15</p>	Frankfurt Hall
12:15 - 13:00	<p>Type: Young Oncologists session Title: YO mentorship session 2</p>	Discussion hub
13:30 - 15:00	<p>Type: Meeting highlights Title: ESMO Breast Cancer 2026 key takeaways</p> <p>Chair(s): Sara Tolaney, United States of America; Nicholas Turner, United Kingdom; Masakazu Toi, Japan</p>	Berlin Hall
13:30 - 13:45	<p>Breast cancer early detection and prevention</p>	
13:45 - 14:00	<p>Translational research</p>	
14:00 - 14:20	<p>Early breast cancer</p>	
14:20 - 14:40	<p>Metastatic breast cancer</p>	



14:40 - 14:55

Supportive care

14:55 - 15:00

Closure of the meeting by the Chairs

[Sara Tolaney](#)¹, [Nicholas Turner](#)², [Masakazu Toi](#)³, ¹Dana Farber Cancer Institute, Boston, United States of America, ²The Royal Marsden Hospital - Chelsea, London, United Kingdom, ³Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan